Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ACVR1 | Q04771 | 7/20 | 0.38 |
| ▸ | PAK4 | O96013 | 1/20 | 0.36 |
| ▸ | JAK2 | O60674 | 1/20 | 0.32 |
| ▸ | IDH1 | O75874 | 1/20 | 0.32 |
| ▸ | NTRK1 | P04629 | 1/20 | 0.32 |
| ▸ | SLC34A1 | Q06495 | 1/20 | 0.31 |
| ▸ | PSEN1 | P49768 | 4/20 | 0.31 |
| ▸ | PSEN2 | P49810 | 4/20 | 0.31 |
| ▸ | APH1B | Q8WW43 | 4/20 | 0.31 |
| ▸ | NCSTN | Q92542 | 4/20 | 0.31 |
| ▸ | APH1A | Q96BI3 | 4/20 | 0.31 |
| ▸ | PSENEN | Q9NZ42 | 4/20 | 0.31 |
| ▸ | KCNH2 | Q12809 | 2/20 | 0.31 |
| ▸ | GRM5 | P41594 | 1/20 | 0.30 |
| ▸ | TYK2 | P29597 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL25201204 | 0.89 | ACVR1 (0.47) | ACVR1PAK4TYK2 | |
| SCHEMBL20589445 | 0.82 | ACVR1 (0.52) | ACVR1PAK4IDH1 | |
| SCHEMBL30095839 | 0.81 | ACVR1 (0.49) | ACVR1 | |
| SCHEMBL25265343 | 0.77 | ACVR1 (0.59) | ACVR1 | |
| SCHEMBL25196878 | 0.77 | ACVR1 (0.59) | ACVR1 | |
| SCHEMBL25520041 | 0.75 | ACVR1 (0.55) | ACVR1PAK4IDH1 | |
| SCHEMBL25201183 | 0.74 | ACVR1 (0.46) | ACVR1PAK4 | |
| SCHEMBL25202146 | 0.74 | ACVR1 (0.43) | ACVR1PAK4TYK2 | |
| SCHEMBL25207467 | 0.74 | ACVR1 (0.51) | ACVR1PAK4JAK2IDH1 | |
| SCHEMBL25195068 | 0.70 | ACVR1 (0.65) | ACVR1PAK4JAK2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240376117-A1 | IMIDAZOLE-CONTAINING INHIBITORS OF ALK2 KINASE | WILMINGTON TRUST, NATIONAL ASSOCIATION | 2024-11-14 | — | — | US | disclosed |
| US-12054492-B2 | Imidazole-containing inhibitors of ALK2 kinase | BIOCRYST PHARMACEUTICALS, INC. (US) | 2024-08-06 | — | — | US | disclosed |
| US-20230271975-A1 | IMIDAZOLE-CONTAINING INHIBITORS OF ALK2 KINASE | WILMINGTON TRUST, NATIONAL ASSOCIATION | 2023-08-31 | — | — | US | disclosed |
| US-20230271975-A1 | IMIDAZOLE-CONTAINING INHIBITORS OF ALK2 KINASE | WILMINGTON TRUST, NATIONAL ASSOCIATION | 2023-08-31 | — | — | US | disclosed |
| US-20230271975-A1 | IMIDAZOLE-CONTAINING INHIBITORS OF ALK2 KINASE | WILMINGTON TRUST, NATIONAL ASSOCIATION | 2023-08-31 | — | — | US | disclosed |
| US-11661426-B2 | Imidazole-containing inhibitors of ALK2 kinase | BIOCRYST PHARMACEUTICALS, INC. (US) | 2023-05-30 | — | — | US | disclosed |
| US-11661426-B2 | Imidazole-containing inhibitors of ALK2 kinase | BIOCRYST PHARMACEUTICALS, INC. (US) | 2023-05-30 | — | — | US | disclosed |
| US-11661426-B2 | Imidazole-containing inhibitors of ALK2 kinase | BIOCRYST PHARMACEUTICALS, INC. (US) | 2023-05-30 | — | — | US | disclosed |
| US-20220332723-A1 | IMIDAZOLE-CONTAINING INHIBITORS OF ALK2 KINASE | WILMINGTON TRUST, NATIONAL ASSOCIATION | 2022-10-20 | — | — | US | disclosed |
| CN-110913855-A | Imidazole-containing ALK2 kinase inhibitors | 拜奥克里斯特制药公司 | 2020-03-24 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230271975-A1 | IMIDAZOLE-CONTAINING INHIBITORS OF ALK2 KINASE | ALK, ACVR2B, ACVR2A | ACVR1 4/4885PAK4 610/4885JAK2 202/4885 |
| US-11661426-B2 | Imidazole-containing inhibitors of ALK2 kinase | ALK, ACVR2B, ACVR2A | ACVR1 4/4885PAK4 610/4885JAK2 202/4885 |
| US-20240376117-A1 | IMIDAZOLE-CONTAINING INHIBITORS OF ALK2 KINASE | ALK, ACVR2B, ACVR2A | ACVR1 4/4885PAK4 610/4885JAK2 202/4885 |
| US-20220332723-A1 | IMIDAZOLE-CONTAINING INHIBITORS OF ALK2 KINASE | ALK, ACVR2B, ACVR2A | ACVR1 4/4885PAK4 610/4885JAK2 202/4885 |
| US-12054492-B2 | Imidazole-containing inhibitors of ALK2 kinase | ALK, ACVR2B, ACVR2A | ACVR1 4/4885PAK4 610/4885JAK2 202/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.